Results for tag: "Cancer CDK Inhibitor"

The Cancer CDK Inhibitor market is a subset of the Oncology Drugs market, focusing on drugs that inhibit the activity of cyclin-dependent kinases (CDKs). CDKs are proteins that regulate the cell cycle, and their inhibition can lead to cell death in cancer cells. CDK inhibitors are used to treat a variety of cancers, including breast, lung, and colorectal cancer. These drugs are typically administered orally or intravenously, and can be used in combination with other cancer treatments. The Cancer CDK Inhibitor market is highly competitive, with many companies developing and marketing these drugs. Some of the major players in the market include Novartis, Pfizer, Merck, AstraZeneca, and Eli Lilly. Other companies, such as Gilead Sciences, Bristol-Myers Squibb, and Celgene, are also active in the market. Show Less Read more